Evidence map›Paper›PMID 39983085›Full record

ArticleBlood advances2025

BR or R-CHOP induction with rituximab maintenance in untreated, transplant-ineligible patients with mantle cell lymphoma.

Katja Gutmair, Diego Villa, Nicholas Cunningham, Elisabeth Silkenstedt, Lisa Rimsza, Colleen Ramsower, David W Scott, Alina S Gerrie, Hanneke C Kluin-Nelemans, Martin Dreyling and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Katja GutmairInstitute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0009-0002-3948-6186
Diego VillaDivision of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-4625-3009
Nicholas CunninghamBelfast Health and Social Care Trust, Belfast, United Kingdom.
Elisabeth SilkenstedtDepartment of Medicine III, University Hospital Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0000-0003-2676-0860
Lisa RimszaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ.
Colleen RamsowerDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ.ORCID 0000-0002-4991-7712
David W ScottDivision of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0002-0435-5947
Alina S GerrieDivision of Medical Oncology, BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-4727-1425
Hanneke C Kluin-NelemansDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-2617-9427
Martin DreylingDepartment of Medicine III, University Hospital Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0000-0002-0358-5249
Eva HosterInstitute for Medical Information Processing, Biometry, and Epidemiology, Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0000-0002-0749-1389

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39983085
PMCPMC12127632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.